top of page
PARTNERS WITH
Osimertinib
MECHANISM OF ACTION
MECHANISM OF KIDNEY INJURY
CLINICAL KIDNEY SYNDROME
CARDIOVASCULAR ADVERSE EFFECTS
LYTE ABNORMALITIES
RISK FACTORS
MITIGATION STRATEGIES
SUGGESTIONS
NOTES/COMMENTS
PHARMACOKINETICS
Molecular Weight
Volume of Distribution
Plasma Protein Binding
Metabolism
Bioavailability
Half-life elimination
Time to peak
Excretion
Dialyzable?
REF:
PATHOLOGY SLIDES:
ENTRY UPDATES:
Nov 7, 2024
bottom of page